All Eli Lilly articles – Page 2

Business

$25bn-plus trade sharpens pharma giants’ focus

2014-04-25T00:00:00Z

Novartis’ asset swaps with GSK and Eli Lilly are the latest steps in an ongoing streamlining process

Business

Missing safety risk emails draw $9bn Actos fine

2014-04-11T00:00:00Z

Judge finds absence of Takeda documentation in bladder cancer case ‘disturbing’

Business

Lilly wins cancer drug patent dispute

2014-04-07T00:00:00Z

Alimta patent will last until 2022 after US court rules in Lilly’s favour

Business

Weathering the storm

2014-01-06T00:00:00Z

Pharmaceutical industry roundup 2013

Business

Lilly freezes pay as patent cliff looms

2013-07-24T00:00:00Z

Drugmaker targets $400 million savings as two key patents near expiry

Business

NHS to offer breast cancer prevention drugs

2013-06-25T00:00:00Z

Five-year course of tamoxifen or raloxifene recommended for high risk women

Business

Patent woes lead to sharp sales losses

2012-10-26T00:00:00Z

Bristol-Myers Squibb, AstraZeneca and Eli Lilly have all suffered loss of exclusivity for key drugs

Business

Alzheimer's drug flops in Phase III

2012-08-24T00:00:00Z

Solanezumab from Eli Lilly missed the cognitive and functional primary endpoints of the trials

Feature

Going with the flow

2012-03-31T00:00:00Z

When it comes to scaling up organic synthesis, it pays to think small